Published in Biotech Law Weekly, September 2nd, 2005
Some of these generics companies are actively contesting the patents of the major research-based firms, and a newly proposed study by Kline & Co. is set to examine the leaders in this movement.
"In the past, the generics companies just used to wait for the patents on brand-name drugs to expire, but now they're being a lot more aggressive and proactive," said Laura Mahecha, healthcare industry manager for Kline's research division. "They're bringing legal challenges to try to break patents in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.